Margaret L. Griffin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Margaret L. Griffin has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Roger D. Weiss
Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, MA, USA
5 shared publications- Roger D. Weiss
Division of Alcohol, Drugs and Addiction McLean Hospital Belmont Massachusetts USA
5 shared publications - R. Kathryn McHugh
Division of Alcohol, Drugs and Addiction McLean Hospital Belmont Massachusetts USA
3 shared publications Fiona S. Graff
Department of Psychiatry, Harvard Medical School and McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States
2 shared publicationsGarrett M. Fitzmaurice
Laboratory for Psychiatric Biostatistics; McLean Hospital; Belmont Massachusetts
2 shared publications- Garrett M. Fitzmaurice
Laboratory for Psychiatric Biostatistics, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA; Department of Biostatistics, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
2 shared publications
Latest Publications
- 27 March 2023
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 49 (4) , 399-405
Assessment of the Short Grit Scale in patients with substance use disorder: Psychometric properties and patient characteristics
Background: Recovery from substance use disorder requires sustained effort and perseverance. Hence, the resilience factor of grit may be important for people in recovery. Little research has been conducted on grit in patients with substance use disorder (SUD), especially in a large and varied sample. Objectives: To analyze the psychometric properties of the Short Grit Scale (Grit-S) in patients with SUD and to use demographic and clinical characteristics to predict variance in Grit-S scores. Methods: Participants completed the Grit-S and other self-report measures. Psychometric properties of the Grit-S were assessed in outpatients (N = 94, 77.7% male) and a hierarchical regression predicted Grit-S variance in inpatients (N = 1238, 65.0% male). Results: The Grit-S demonstrated good internal consistency (α=.75) and strong test-retest reliability (adjusted r = .79, p < .001). Mean Grit-S score was 3.15, lower than other clinical samples reported in the literature. Regression modeling indicated a moderate, statistically significant association between demographic and clinical characteristics and Grit-S scores (R2 = 15.5%, p < .001). Of particular interest, the positive factor of recovery protection showed the strongest association with Grit-S of all variables assessed (β=.185 vs. β = .052–.175 for the remaining significant independent variables). Conclusion: The psychometric properties of the Grit-S in patients with SUD support its use in this population. Moreover, the particularly low grit scores among inpatients with SUDs and the association of grit scores with substance use risk and recovery factors suggest that grit could be useful as a treatment target in this population.
- 27 March 2023
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 49 (4) , 399-405
Assessment of the Short Grit Scale in patients with substance use disorder: Psychometric properties and patient characteristics
Background: Recovery from substance use disorder requires sustained effort and perseverance. Hence, the resilience factor of grit may be important for people in recovery. Little research has been conducted on grit in patients with substance use disorder (SUD), especially in a large and varied sample. Objectives: To analyze the psychometric properties of the Short Grit Scale (Grit-S) in patients with SUD and to use demographic and clinical characteristics to predict variance in Grit-S scores. Methods: Participants completed the Grit-S and other self-report measures. Psychometric properties of the Grit-S were assessed in outpatients (N = 94, 77.7% male) and a hierarchical regression predicted Grit-S variance in inpatients (N = 1238, 65.0% male). Results: The Grit-S demonstrated good internal consistency (α=.75) and strong test-retest reliability (adjusted r = .79, p < .001). Mean Grit-S score was 3.15, lower than other clinical samples reported in the literature. Regression modeling indicated a moderate, statistically significant association between demographic and clinical characteristics and Grit-S scores (R2 = 15.5%, p < .001). Of particular interest, the positive factor of recovery protection showed the strongest association with Grit-S of all variables assessed (β=.185 vs. β = .052–.175 for the remaining significant independent variables). Conclusion: The psychometric properties of the Grit-S in patients with SUD support its use in this population. Moreover, the particularly low grit scores among inpatients with SUDs and the association of grit scores with substance use risk and recovery factors suggest that grit could be useful as a treatment target in this population.
- 1 December 2019
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 205, 107612
Suicidal motivations reported by opioid overdose survivors: A cross-sectional study of adults with opioid use disorder
- 1 December 2019
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 205, 107612
Suicidal motivations reported by opioid overdose survivors: A cross-sectional study of adults with opioid use disorder
- 1 June 2016
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 163, 216-221
Longitudinal association between pain severity and subsequent opioid use in prescription opioid dependent patients with chronic pain
- 1 June 2016
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 163, 216-221
Longitudinal association between pain severity and subsequent opioid use in prescription opioid dependent patients with chronic pain
- 24 March 2015
- Published by Wiley in The American Journal on Addictions
- Vol. 24 (4) , 308-314
Health-related quality of life among prescription opioid-dependent patients: Results from a multi-site study
Background Although prescription opioid use disorder has recently increased sharply in the United States, relatively little is known about the general well‐being of this population. Assessment of quality of life in patients with substance use disorders has been recommended to improve clinical care. Objectives Health‐related quality of life was examined in prescription opioid‐dependent patients at entry to a national multi‐site clinical trial, to compare quality of life scores in the study sample to other populations; further, background variables associated with quality of life in the literature were examined. Methods Prescription opioid‐dependent patients (N = 653) were compared to general populations on the Medical Outcome Study Short Form‐36 (SF‐36) quality of life measure; and the association between patient background variables and quality of life was examined. Results Compared to a general population, the current sample of prescription opioid‐dependent patients had worse physical (−1.7 points, p < .001) and mental quality of life (−12.3 points, p < .001) as measured by the SF‐36, similar to other opioid‐use disorder populations. Within our sample, women showed more impairment than men in mental quality of life (−4.3 points, p < .001); older patients scored worse on physical (−5.2 points, p < .001), but not mental, quality of life. Chronic pain was associated with poorer physical quality of life (−9.0 points, p < .001). Conclusions and scientific significance The growing focus on wellness underscores the importance of measuring quality of life in addition to substance use outcomes. Routine assessment of health‐related quality of life can add an important dimension to overall evaluation of patients' treatment response. (Am J Addict 2014;XX:1 –7)
- 24 March 2015
- Published by Wiley in The American Journal on Addictions
- Vol. 24 (4) , 308-314
Health-related quality of life among prescription opioid-dependent patients: Results from a multi-site study
Background Although prescription opioid use disorder has recently increased sharply in the United States, relatively little is known about the general well‐being of this population. Assessment of quality of life in patients with substance use disorders has been recommended to improve clinical care. Objectives Health‐related quality of life was examined in prescription opioid‐dependent patients at entry to a national multi‐site clinical trial, to compare quality of life scores in the study sample to other populations; further, background variables associated with quality of life in the literature were examined. Methods Prescription opioid‐dependent patients (N = 653) were compared to general populations on the Medical Outcome Study Short Form‐36 (SF‐36) quality of life measure; and the association between patient background variables and quality of life was examined. Results Compared to a general population, the current sample of prescription opioid‐dependent patients had worse physical (−1.7 points, p < .001) and mental quality of life (−12.3 points, p < .001) as measured by the SF‐36, similar to other opioid‐use disorder populations. Within our sample, women showed more impairment than men in mental quality of life (−4.3 points, p < .001); older patients scored worse on physical (−5.2 points, p < .001), but not mental, quality of life. Chronic pain was associated with poorer physical quality of life (−9.0 points, p < .001). Conclusions and scientific significance The growing focus on wellness underscores the importance of measuring quality of life in addition to substance use outcomes. Routine assessment of health‐related quality of life can add an important dimension to overall evaluation of patients' treatment response. (Am J Addict 2014;XX:1 –7)
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e19
Does early response to buprenorphine-naloxone predict treatment outcome in prescription opioid dependence?
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e19
Does early response to buprenorphine-naloxone predict treatment outcome in prescription opioid dependence?
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e34-e35
Anxiety sensitivity and the discrepancy between motivation to change and perceived ability to change
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e34-e35
Anxiety sensitivity and the discrepancy between motivation to change and perceived ability to change
- 12 November 2013
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 40 (2) , 157-162
Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder
Background: Given the growing prevalence of prescription opioid dependence and the considerable rates of additional psychopathology in drug dependence, we examined the association between the presence of a co-occurring Axis I psychiatric disorder and sociodemographic and clinical characteristics in this secondary analysis of patients entering a treatment study for dependence on prescription opioids. Treatment outcomes were also compared. Methods: Patients dependent on prescription opioids participated in a multi-site, two-phase, randomized, controlled trial to assess different lengths of buprenorphine-naloxone pharmacotherapy and different intensities of counseling (Clinicaltrials.gov identifier: NCT00316277). Among the 653 participants entering the first phase of the trial, 360 entered the second phase, receiving 12 weeks of buprenorphine-naloxone treatment; they are reported here. Half of those participants (180/360) had a current co-occurring psychiatric disorder in addition to substance dependence. Results: Sociodemographic characteristics were similar overall between those with and without a co-occurring psychiatric disorder, but women were 1.6 times more likely than men to have a co-occurring disorder. On several clinical indicators at baseline, participants with a co-occurring disorder had greater impairment. However, they had better opioid use outcomes at the conclusion of 12 weeks of buprenorphine-naloxone stabilization than did participants without a co-occurring disorder. Conclusions: Prescription opioid–dependent patients with a co-occurring psychiatric disorder had a better response to buprenorphine-naloxone treatment despite demonstrating greater impairment at baseline. Additional research is needed to determine the mechanism of this finding and to adapt treatments to address this population.
- 12 November 2013
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 40 (2) , 157-162
Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder
Background: Given the growing prevalence of prescription opioid dependence and the considerable rates of additional psychopathology in drug dependence, we examined the association between the presence of a co-occurring Axis I psychiatric disorder and sociodemographic and clinical characteristics in this secondary analysis of patients entering a treatment study for dependence on prescription opioids. Treatment outcomes were also compared. Methods: Patients dependent on prescription opioids participated in a multi-site, two-phase, randomized, controlled trial to assess different lengths of buprenorphine-naloxone pharmacotherapy and different intensities of counseling (Clinicaltrials.gov identifier: NCT00316277). Among the 653 participants entering the first phase of the trial, 360 entered the second phase, receiving 12 weeks of buprenorphine-naloxone treatment; they are reported here. Half of those participants (180/360) had a current co-occurring psychiatric disorder in addition to substance dependence. Results: Sociodemographic characteristics were similar overall between those with and without a co-occurring psychiatric disorder, but women were 1.6 times more likely than men to have a co-occurring disorder. On several clinical indicators at baseline, participants with a co-occurring disorder had greater impairment. However, they had better opioid use outcomes at the conclusion of 12 weeks of buprenorphine-naloxone stabilization than did participants without a co-occurring disorder. Conclusions: Prescription opioid–dependent patients with a co-occurring psychiatric disorder had a better response to buprenorphine-naloxone treatment despite demonstrating greater impairment at baseline. Additional research is needed to determine the mechanism of this finding and to adapt treatments to address this population.
- 1 January 2011
- Published by Wiley in The American Journal on Addictions
- Vol. 20 (2) , 100-105
The Impact of Drug Use in Social Networks of Patients with Substance Use and Bipolar Disorders
In this exploratory analysis, we assessed the effect of drug use among social‐network members on recovery from drug dependence in patients with co‐occurring bipolar disorder. Patients (n = 57) enrolled in a group therapy study completed assessments over 15 months. Patients with zero to one drug users in their social networks at intake had few days of drug use during treatment and follow‐up, whereas those with ≥2 drug users had significantly more days of drug use. Multivariate analysis showed that patients who consistently named multiple drug users in their social networks had a marked increase in drug use over 15 months, while those who never or occasionally named multiple drug users had a small decline in drug use over time. Multiple drug users in social networks of treatment‐seeking drug‐dependent patients with co‐occurring bipolar disorder may indicate poor drug use outcomes; efforts to reduce the association with drug users may be useful. This clinical trial has been registered in a public trials registry at clinicaltrials.gov (identifier is NCT00227838). (Am J Addict 2011;20: 1–6)
- 1 January 2011
- Published by Wiley in The American Journal on Addictions
- Vol. 20 (2) , 100-105
The Impact of Drug Use in Social Networks of Patients with Substance Use and Bipolar Disorders
In this exploratory analysis, we assessed the effect of drug use among social‐network members on recovery from drug dependence in patients with co‐occurring bipolar disorder. Patients (n = 57) enrolled in a group therapy study completed assessments over 15 months. Patients with zero to one drug users in their social networks at intake had few days of drug use during treatment and follow‐up, whereas those with ≥2 drug users had significantly more days of drug use. Multivariate analysis showed that patients who consistently named multiple drug users in their social networks had a marked increase in drug use over 15 months, while those who never or occasionally named multiple drug users had a small decline in drug use over time. Multiple drug users in social networks of treatment‐seeking drug‐dependent patients with co‐occurring bipolar disorder may indicate poor drug use outcomes; efforts to reduce the association with drug users may be useful. This clinical trial has been registered in a public trials registry at clinicaltrials.gov (identifier is NCT00227838). (Am J Addict 2011;20: 1–6)
- 31 October 2009
- Published by Elsevier in Addictive Behaviors
- Vol. 34 (10) , 826-829
Measuring principal substance of abuse in comorbid patients for clinical research
- 31 October 2009
- Published by Elsevier in Addictive Behaviors
- Vol. 34 (10) , 826-829
Measuring principal substance of abuse in comorbid patients for clinical research
- 1 April 2008
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 94 (1-3) , 272-275
Predictors of dropout from group therapy among patients with bipolar and substance use disorders
- 1 April 2008
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 94 (1-3) , 272-275
Predictors of dropout from group therapy among patients with bipolar and substance use disorders